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Liver TransplantationEndothelial Dysfunction in Steatotic Human Donor
Livers: A Pilot Study of the Underlying Mechanism
During Subnormothermic Machine Perfusion
Irene Beijert, MD,1,2 Safak Mert, PhD,1 Viola Huang, MD,1 Negin Karimian, MD,1 Sharon Geerts, BSc,1
Ehab O.A. Hafiz, MD,1,3 James F. Markmann, MD,4 Heidi Yeh, MD,4 Robert J. Porte, MD, PhD,2
and Korkut Uygun, PhD1Background.Steatosis is a major risk factor for primary nonfunction in liver transplantations. Steatotic livers recover poorly from
ischemia reperfusion injury, in part due to alterations in the microcirculation, although the exact mechanism is unclear. In this study,
we tested if there were any alterations in the shear stress sensing Kruppel-like factor 2 (KLF2) and its likely downstream conse-
quences in the ex vivo perfused human liver endothelium, which would imply perturbations in microcirculatory flow in
macrosteatotic livers disrupts laminar flow to evaluate if this is a potential therapeutic target for steatotic livers.Methods. Using
a subnormothermicmachine perfusion system, 5macrosteatotic and 4 nonsteatotic human livers were perfused for 3 hours. Flow,
resistance, and biochemical profile were monitored. Gene expression levels of nitric oxide synthase 3 (eNOS), KLF2, and
thrombomodulin were determined. Nitric oxide (NO) was measured in the perfusion fluid and activation of eNOS was measured
with Western blotting.Results. Flow dynamics, injury markers, and bile production were similar in both groups. Kruppel-like fac-
tor 2 expression was significantly higher in nonsteatotic livers. Western blotting analyses showed significantly higher levels of ac-
tivated eNOS in nonsteatotic livers, consistent with an increase in NO production over time. Macrosteatotic livers showed
decreased KLF2 upregulation, eNOS activity, and NO production during machine perfusion. Conclusions. These results indi-
cate a perturbed KLF2 sensing in steatotic livers, which aligns with perturbed microcirculatory state. This may indicate endothelial
dysfunction and contribute to poor posttransplantation outcomes in fatty livers, and further studies to confirm by evaluation of flow
and testing treatments are warranted.
(Transplantation Direct 2018;4: e345; doi: 10.1097/TXD.0000000000000779. Published online 23 April, 2018.)W ith about 120 000 patients on the waiting list for or-gan transplantation in the United States, there is an
enormous gap between the need for and availability of suit-
able organs for transplant. Because of this shortage, aboutReceived 2 January 2018.
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2 Transplantation DIRECT ■ 2018 www.transplantationdirect.comthat were previously considered unsuitable has extended the
donor pool significantly.3,4 Because of a serious shortage of
donor organs suitable for transplant, livers with suboptimal
quality, such as steatotic livers, are increasingly considered
for transplantation. However, transplantation of such grafts
is associated with a higher risk of posttransplantation com-
plications, morbidity, and mortality.5-8
Hepatic steatosis, resulting from abnormal accumulation
of triacylglycerol in the cytoplasm of hepatocytes, is an im-
portant factor affecting the function of donor livers. Steatosis
is estimated to be present in up to 50% of organ donors. Be-
cause of the current epidemic of obesity, this is likely to continue
to increase.9 Although steatosis can diminishwithin weeks after
transplantation, early functional recovery is still impaired.
Grafts with severe macrovesicular steatosis (>60% of hepato-
cytes involved) are often discarded because of the high inci-
dence of primary nonfunction after transplantation. The use
of grafts with moderate steatosis (30-60% of hepatocytes in-
volved), however, remains a challenging question. Primary
nonfunction rates in this group are as high as 15%, whereas
delayed graft function rates may reach 35%.4-7 Collett et al10
recently developed aUKDonor Liver Index including steatosis
as risk factor for short-term graft failure. Thus, although use of
these marginal grafts may be an effective way to decrease the
discrepancy between organ supply and demand, they still bear
a considerable risk for the development of several severe com-
plications and graft loss.11 Ischemia-reperfusion (I/R) injury is
considered to be the main cause of liver graft dysfunction after
transplantation, independent of liver basal characteristics.12,13
Steatotic livers are especially sensitive to I/R injury, in part
due to alterations in the microcirculation, although the exact
mechanism is unclear.14,15 Minimizing the adverse effects of
I/R injury could increase the number of suitable steatotic
grafts. This small-scale, pilot study aims to test if there are dif-
ferences in shear stress sensing between macrosteatotic and
nonsteatotic human donor livers. Such a sensory failure may
lead to an endothelial dysfunction and contributing to poor
posttransplantation outcomes. In particular, identifying such
differences in human donor livers would indicate the likeli-
hood that this is a clinically relevant target for further studies.
The liver sinusoidal endothelial cells are not only a physical
barrier but also regulate hepatic vascular tone, contribute to
hemostasis, thrombosis, inflammation, and angiogenesis.16
They are also one of the major targets of shear stress created
by the blood flow. Shear stress affects many cell types in the
liver, including hepatocytes and immune cells of the liver
(like Kupffer cells, and intrahepatic leukocytes). As a result,
mechanosensory stimulation may affect many systems while
altering the endothelial response to shear stress.17 Targeting
the Kruppel-like-factor (KLF)2 and endothelial nitric oxide
synthase (eNOS) system, we tried to investigate a well-defined,
narrow field of effects particularly altering flow dynamics and
endothelial function. Endothelial cells are able to sense varia-
tions of flow in reaction to changing shear stress that in turn reg-
ulates endothelial gene expression and generate vasodilator
agents to reestablish the blood pressure.18 Fat droplet accumu-
lation in the hepatocytes, as in hepatic macrosteatosis, increases
cell volume and results in partial or complete obstruction of the
hepatic sinusoidal space and is known to subsequently lead to a
reduced sinusoidal blood flow.15 The degree of fat accumula-
tion in the cytoplasm of the hepatocytes is inversely related to
both total hepatic blood flow and flow in the microcirculationand worsens after brain death in several animal models.19,20
Flow cessation or disturbed flow in themicrocirculation triggers
acute endothelial dysfunction in part due to a reduced expres-
sion of vasoprotective transcription factors.21
Evidence suggests that KLF2 acts as a key regulator of
normal endothelium function and physiology.14,22 It has been
estimated that flow-mediated KLF2 regulates 109 genes,
representing 15.3% of the total number of genes regulated
by flow.23 Kruppel-like factor 2 is expressed almost exclu-
sively in endothelial cells and is selectively induced by a bio-
mechanical stimulus caused by laminar flow (shear stress)
through activation of the MEK5/ERK5 pathway which in
turn activates myocyte enhancer factor 2, a transcription fac-
tor that upregulates KLF2 expression.23-25 Kruppel-like factor
2 induces expression of vasoprotective and anti thrombotic
genes, such as thrombomodulin (TM) and eNOS.26 Besides
transcriptional regulation by KLF2, regulation of eNOS ac-
tivity is mediated by shear stress as well. One of the major
activating posttranslational modifications for eNOS is phos-
phorylation of serine 1177 (ser-1177) via AKTand PKA.27-29
When ser-1177 is phosphorylated in response to increased
shear stress, nitric oxide (NO) production increases twofold
to threefold above baseline levels.27 Steady laminar flow en-
hances the expression of vasoprotective genes eNOS and
TM through KLF2 and regulates the activation of eNOS.
Conversely, disturbed flow or lack of flow, causing low to
no shear stress, enhances the expression of proinflammatory,
proapoptotic, and procoagulant genes and downregulates
vasoprotective genes.30,31
Subnormothermic machine perfusion (SNMP) provides a
good experimental model to test differences in shear stress
sensing between macrosteatotic and nonsteatotic livers. As
we demonstrated in prior studies,32,33 3 hours of SNMP is
sufficient for many relevant recovery mechanisms in particu-
lar adenosine triphosphate recovery, and stabilization of arte-
rial resistance. Similarly, NO producing sensory systems can
be activated within minutes34,35 and the mediator of the re-
sponse, NO has a very short half-life.Moreover, it is operation-
ally practical, and does not require availability of type-matched,
fresh human blood which a reperfusion model would need.36
To determine whether macrosteatosis impaired shear stress-
responsive components of the NO pathway, we evaluated
KLF2, eNOS, and TM gene expression, eNOS phosphoryla-




Steatotic and nonsteatotic donor human livers from do-
nors aged 18 to 60 years that were declined for transplanta-
tion due to various reasons were obtained from the New
England Donor Services with consent for research. Livers
with viral infection or major surgical lacerations were ex-
cluded. In total, n = 9 livers were included to the study,
consisting of n = 5macro-steatotic and n = 4 nonsteatotic livers.
This study was exempted by the institutional review board of
Massachusetts General Hospital (protocol 2011P001496).
Donor warm ischemia time (DWIT) was defined as the time
fromwithdrawal of life support to cold flush.Cold ischemia time
(CIT)was defined as the time from cold flush to reperfusion.De-
tails of donor and graft characteristics can be found in Table 1.
TABLE 1.
Donor and graft characteristics
Nonsteatotic 1 2 3 4
Donation type (DCD/DBD) DCD DCD DCD DCD
Reason rejected Prolonged/unknown down-time Prolonged/unknown down-time Age, DCD, +EtOH
Sex Male Male Male Male
Age, y 18 55 49 49
BMI 25 35 27 29
Cause of death Anoxia/Asphyxiation Cardiac Arrest Hemorrhagic Stroke Anoxia
DWIT, min 20 N/A 33 30
CIT, min 636 949 735 713
Macrosteatosis, % <10 10-30 20-30 <10
Steatotic 1 2 3 4 5
Donation type (DCD/DBD) DCD DCD DBD DCD DBD
Reason rejected Anoxia, heavy EtOH BMI Steatosis Age, steatosis, EtOH, DCD IVDA
Sex
Age, y 49 47 50 56 53
BMI 26 35 29 24 32
Cause of death Anoxia/Cardiac Arrest Stroke Anoxia/cardiac arrest Anoxia/drowning Anoxia, drugs intoxication
DWIT, min N/A 45 0 45 0
CIT, min 808 533 381 438 705
Macrosteatosis, % >60 >60 80 >60 50
BMI, body mass index; EtOH, ethyl alcohol; IVDA, intravenous drug abuse.
© 2018 Wolters Kluwer Beijert et al 3Perfusion and Tissue Sampling
Weused the SNMPmodel described previously by our group
(Figure 1).33 Briefly, we performed a 3-hour perfusion.Williams
E-based supplementedmediawas been used for SNMPat 7mm
Hg portal, and 70 to 80 mmHg hepatic artery (HA) pressures.
Media was oxygenated continuously and routine biochemical
and chemical screening was taken throughout the perfusion.
Tissue samples were collected hourly, whereas perfusate sam-
plings take place every 10 minutes for the first 30 minutes and
then once in every 30 minutes. Further details can be found at
SDC,Materials andMethods (http://links.lww.com/TXD/A80).
Scoring Steatosis
The percentage of steatosis was scored by 2 blinded experts
(a pathologist and a liver transplant surgeon) by estimating
the percent hepatocytes containing macrovesicular lipid drop-
lets on hemotoxylin and eosin–stained sections using lightFIGURE 1. Schematic representation of perfusion system. The perfusi
portal, each with their own pump, oxygenator using carbogen gas (95%microscopy. Steatosis was defined as ≥50% macro-steatosis,
and only macro-steatotic livers are included into the analyses
along with lean controls. Scoring results are provided in
Table 2 and representative images of macrosteatotic and lean
livers can be seen in Figure 2.
Gene Expression Analyses, Western Blot Analyses and
NO Measurements
Quantitative reverse transcription polymerase chain reac-
tion was used to determine gene expression levels of KLF2,
eNOS, and TM. To verify the presence of endothelial cells,
CD31 was used as the marker gene. Specific primers with
the sequences shown in Table 3 were synthesized by the
Massachusetts General Hospital DNA Core. Endothelial nitric
oxide synthase activation was evaluated by determining the
serine phosphorylation at S-1177. Timewise collected tissue
samples were directed to phospho S1177 specific p-eNOSon system incorporated 2 independent circulations: an arterial and a
O2, 5% CO2), bubble trap, pressure, and flow meter.
TABLE 2.
Macrosteatosis scores of each liver
Liver no. Classification First expert Second expert
1 Lean <10% <5%
2 Lean 10-30% <5%
3 Lean 20-30% 25%
4 Lean <10% <5%
5 Macrosteatotic >60% 50%
6 Macrosteatotic ~80% 100%
7 Macrosteatotic >60% 50%
8 Macrosteatotic >60% 100%
9 Macrosteatotic >60% >60%
Blinded experts scored each liver independently for macrosteatosis.
TABLE 3.
Primer sequences for qPCR analyses of targeted genes
Gene Accession no. Primer Sequence
GAPDH NM_002046.4 Forward 5′-ACCCACTCCTCCACCTTTGA-3′
Reverse 5′-CATACCAGGAAATGAGCTTGACAA-3′
CD31 NM_000442.2 Forward 5′-GACCTCGCCCTCCACAAA-3′
Reverse 5′-CGTGTCTTCAGGTTGGTATTTCAC-3′
KLF2 NM_016270.2 Forward 5′-GCAAGACCTACACCAAGAGTTCG-3′
Reverse 5′-TCCCA GTTGCAGTGGTAGGG-3′
TM NM_001993.4 Forward 5′-TGATTCCCTCCCGAACAGTT-3′
Reverse 5′-ACTCTACCGGGCTGTCTGTACTCT-3′
eNOS NM_000603.4 Forward 5′-TGTATGGATGAGTATGACGTGGTGT-3′
Reverse 5′-TGCAAAGCTCTCTCCATTCTCC-3′
ACTB NM_001101 Forward 5′-GCACAGAGCCTCGCCTT-3′
Reverse 5′-CCTTGCACATGCCGGAG-3′
HPRT-1 NM_000194 Forward 5′-TCCTCCTCCTGAGCAGTCA-3′
Reverse 5′-ACCCTTTCCAAATCCTCAGC-3′
Primers are generated through Primer-BLAST, NIH.
ACTB, β-actin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HPRT-1, hypoxanthine
phosphoribosyltransferase; qPCR, quantitative polymerase chain reaction.
4 Transplantation DIRECT ■ 2018 www.transplantationdirect.comWestern blot analyses (Figure S1 http://links.lww.com/
TXD/A81). Finally, NO levels were measured from the col-
lected perfusate by a colorimetric assay. Further details can
be found at SDC, Materials and Methods (http://links.
lww.com/TXD/A80).
Statistical Analysis
Continuous variables are presented as medians and inter-
quartile range (IQR). As the data are not normally distributed
in all cases, and there are only 2 groups,Mann-WhitneyU test
was used for continuous variables between the 2 experimental
groups, and Wilcoxon Signed Rank was used for comparison
within groups. Correlations between variables were tested
with Spearman rho correlation, a nonparametric version of
the Pearson test. Variables with a P value of 0.05 or less were
considered to be significant. All statistical analyses were done
with IBM SPSS version 23 for Mac, and graphs were made
with Graphpad Prism 6 for Mac.
RESULTS
Donor and Graft Characteristics
A total of 4 nonsteatotic and 5 steatotic discarded human
livers were perfused (Table 1). All the nonsteatotic livers were
donated after circulatory death (DCD), with a median CITof
713 (IQR, 674.5-724) minutes and a median DWIT of 30FIGURE 2. Representative images of lean (A) andmacrosteatotic (B) live
at the beginning and the end of perfusion for hemotoxylin and eosin stai
from 1 lean (panel A) and 1 macrosteatotic (panel B) liver showing postpe
whereas sinusoids can be barely visible (white arrow). No significant fibro(IQR, 25-31.5) minutes. Two of the steatotic livers were do-
nated after brain death (DBD) and 3 were DCD with a me-
dian CIT of 485 (IQR, 438-533) minutes and a median
warm ischemia time (WIT) of 22.5 (IQR, 0-46.5) minutes.
Functional Measurements on SNMP
Portal vein (PV) resistance was similar between steatotic and
nonsteatotic livers (Figure 3A). Hepatic artery resistance
trended higher in steatotic than nonsteatotic livers (Figure 3B),
but this difference was not statistically significant because
of the variability in resistances seen. Lactate clearance, bile
production, and alanine transaminase levels were similar
between steatotic and nonsteatotic livers (Table S1, http://
links.lww.com/TXD/A82).
KLF2 Messenger Ribonucleic Acid Is Upregulated in
Normal Livers, But Not in Steatotic Livers
Kruppel-like factor 2 was significantly upregulated in both
groups at the end of SNMP compared with the start ofrs at 20 objectivemagnification. Liver tissue samples were collected
ning scoring for macrosteatosis. Representative images are obtained
rfusion state. Large fat droplets are prevailing in panel B (black arrow),
sis has been detected in any of the samples.
FIGURE 3. Resistance in the PV (A) and the HA (B) calculated as quotient of pressure and flow. Hepatic artery and PV resistance decreased
gradually throughout perfusion in both nonsteatotic and steatotic livers. However, no statistically significant differenceswere observed between
the 2 groups (data are presented as median ± IQR).
© 2018 Wolters Kluwer Beijert et al 5SNMP (median fold change of 15.88 (P = 0.034) for
nonsteatotic and 3.13 (P = 0.040) for steatotic livers). The de-
gree of upregulation was significantly higher in nonsteatotic
compared to steatotic livers (P = 0.032) (Figure 4A). Although
messenger ribonucleic acid (mRNA) levels of KLF2 inducible
genes eNOS and TM showed an increasing trend during
perfusion, this was not statistically significant (Figure 4B and
C, respectively).NO Levels Increase in Normal Livers, But Not
Steatotic Livers
Nitric oxide concentration in the nonsteatotic livers in-
creased from a median of 5.37 μMat the beginning of perfu-
sion to 7.12 μMafter 3 hours of perfusion (P = 0.055). Nitric
oxide levels in the steatotic group shows a decreasing trend
from a median of 11.73 μM at the beginning of perfusion
(T = 0) to 7.57 μMat the end of perfusion (T = 180) although
this trend was not significant (P = 0.142). Even though the
levels of NO had a decreasing trend in steatotic livers, it
still remained higher at the end of SNMP compared withnonsteatotic livers but this was not statistically significant
either (P = 0.365) (Figure 5A).
Nitric oxide levels in nonsteatotic livers had an increasing
trend with a median fold change of 1.33 (P = 0.055) at the
end of SNMP; while steatotic livers, although not significant,
showed a decreasing trendwith amedian fold change of 0.67 at
the end of SNMP (P = 0.143). Fold change between both
groups did, however, alter significantly (P = 0.05) (Figure 5b).
Other notable donor graft characteristics besides macro-
steatosis are CIT and WIT. Increasing WIT was associated
with lower tissue NO at T = 180 (P = 0.037). Increasing
CIT, on the other hand, was associated with lower tissue NO
at T = 0 (P = 0.042) and higher fold change (P = 0.005). In-
creasing macrosteatosis was associated with decrease in NO
concentration over time (P = 0.05). Correlations between
NO production and macrosteatosis, CIT and WIT are shown
in Table 4.
Activated eNOS Levels Higher in Nonsteatotic Livers
We used ser-1177 phosphorylated eNOS as a surrogate for
eNOS activity in the organs. Although variability was much
FIGURE 4. Gene expression analyses. SNMP induces upregulation of KLF2 in both steatotic and nonsteatotic livers although significantly
more in the nonsteatotic livers (A). eNOS is not significantly more expressed at the end of SNMP in both steatotic and nonsteatotic livers (B).
Thrombomodulin is not significantly more expressed at the end of SNMP in both steatotic and nonsteatotic livers (C). Fold change is calculated
from T=0 for each liver (data are presented as median ± IQR).
6 Transplantation DIRECT ■ 2018 www.transplantationdirect.comwider in nonsteatotic livers, every single nonsteatotic liver
had higher p-eNOS levels than all the steatotic livers, which
had uniformly low activated (ie, phosphorylated) eNOS
levels at all time points (P < 0.005, Figure 6).DISCUSSION AND CONCLUSION
Elucidating the exact mechanisms of steatotic livers' poor
transplantation outcomes is not a straightforward endeavor.
Here, we investigated 1 potential contributor: perturbation
of the microcirculation due to impingement of large lipidFIGURE 5. NO measurements. Absolute NO concentration increased
steatotic livers (A). Relative NO production calculated as fold change from
in the nonsteatotic livers but did not change in steatotic livers (data are pvacuoles into the sinusoids, attenuating vasoprotective sig-
naling events. In a preliminary study of discarded human
livers, we found evidence of impaired NO pathway activation
in steatotic livers compared to nonsteatotic livers. During
SNMP, endothelial cells in steatotic livers fail to upregulate
KLF2, a transcription factor induced in response to shear
stress, to the extent seen in nonsteatotic livers. Tissue levels
of end-effector molecule NO increased only 40% the amount
seen in nonsteatotic livers.
Interestingly, although KLF2 induces eNOS expression,
there was no difference in eNOS and TM mRNA levelsin the nonsteatotic livers throughout SNMP but did not change in
T = 0 for each liver (B). Relative NO production fold change increased
resented as median ± IQR).
TABLE 4.
Correlations between NO production and donor graph
characteristics (data are presented with the Spearman rank
correlation coefficient)
Correlation coefficient (r) P
WIT
NO at T = 0, μM −0.100 0.873
NO at T = 180, μM −0.900 0.037*
NO (fold change) at T = 180 −0.600 0.285
CIT
NO at T = 0, μM −0.829 0.042*
NO at T = 180, μM 0.029 0.957
NO (fold change)at T = 180 0.955 0.005*
Macrosteatosis (%)
NO at T = 0, μM 0.638 0.173
NO at T = 180, μM −0.232 0.658
NO (fold change)at T = 180 −0.812 0.050*
© 2018 Wolters Kluwer Beijert et al 7between steatotic and nonsteatotic livers seen during the pe-
riod of SNMP in our study. It is possible that 3 hours is not
long enough for KLF2-dependent gene transcription to in-
crease, especially at subnormothermic temperatures when
cellular metabolism and biochemistry are slower than at
physiologic temperatures, and that longer perfusion times
would allow us to detect differences. Thus, the lower NO
levels in steatotic livers are likely the result of decreased
eNOS phosphorylation and activity. Indeed, when comparing
posttranslational modification in steatotic versus nonsteatotic
livers, eNOS was phosphorylated to a much lesser extent in
steatotic livers. Activation of eNOS through phosphorylation
of Ser1177 increases in response to shear stress via KLF2-
independent caveolin signaling pathways, which does not re-
quire new transcription or translation, and can therefore occur
in a very short time frame.27-29Heterogeneity in donor charac-
teristics does make it difficult to interpret results in this small
study. For example, little is known about warm ischemia de-
rived endothelial damage, as most studies have focused onFIGURE 6. Normalized levels of eNOS phosphorylation. Levels of eNO
pared with steatotic livers (data are presented as median ± IQR).cold ischemia and reperfusion. However, increased cell death
has been described in endothelial cell cultures exposed to
warm ischemia and reoxygenation.37 Furthermore, Hide
et al38 recently found a negative correlation between warm is-
chemia and NO production in a reperfusion animal model.
We found a negative correlation between DWIT and NO
concentrations at T = 0. Although the low number of repli-
cates require caution, this correlation may explain the seem-
ingly paradoxical higher levels of immediate postcold storage
(T = 0) NO levels in steatotic livers compared with non-
steatotic livers. Two of five steatotic livers were DBD livers,
and thus did not suffer from warm ischemia during with-
drawal of life support, whereas all of the nonsteatotic livers
were DCD livers with notable DWIT. The lower baseline
values of NO in nonsteatotic livers, after a cold-storage pe-
riod without perfusion, may reflect endothelial damage or re-
duction of NO to inorganic nitrite and nitrate during DWIT
(hence results with lower readings) in the nonsteatotic livers,
rather than any genuine response to shear stress. Notably,
our steatotic livers had lower WIT than the nonsteatotic
livers and still failed to increase NO tissue levels during
SNMP, so our findings are not likely to be the result of
WIT variation andmore likely to be due to the steatosis. Endo-
thelial cells may become dysfunctional due to warm ischemia,
diminishing NO synthesis capacity, which is compounded in
steatotic livers by the failure to upregulate NO synthesis be-
cause of disturbed shear stress patterns.
Another important donor graft characteristic was CIT. We
found a negative correlation betweenNO levels at the start of
SNMP and CIT (r = −0.829 P = 0.042), which is not surpris-
ing, as it is known that endothelial cells are more vulnerable
to cold ischemia than hepatocytes. However, this correlation
disappeared over the course of SNMP and instead the fold in-
crease inNOwas more pronouncedwith longer CIT. In vitro
studies have shownendothelial cells can tolerate up to9 hours
of cold ischemia with reversible damage but deteriorate rap-
idly afterward. After 24 h of cold ischemia, the vast majority
of endothelial cells are no longer viable.39-41 Because our av-
erage CIT was less than 12 hours, endothelial cells may stillS phosphorylation are significantly higher in non-steatotic livers com-
8 Transplantation DIRECT ■ 2018 www.transplantationdirect.combe largely viable. The question remains whether our first
finding is a reflection of NO degradation during longer CIT
or endothelial cell dysfunction. However, as endothelial cells
recovered during SNMP, NO synthesis caught up and
surpassed that of organs with shorter CIT to achieve simi-
lar NO levels at T = 180 (data not shown). This may be
an indication that SNMP can repair cells and not just slow
the decay that occurs in cold storage. Furthermore, various
animal models were used to study the effects of cold ische-
mia, mostly lacking the influence of prior warm ischemia.
Again, our steatotic livers also had shorter CIT than the
nonsteatotic controls, and thus the failure of steatotic livers
to produce NO would likely have been even more pro-
nounced if we had equalized CIT. Better elucidation of en-
dothelial injury during warm and cold ischemia may be
better accomplished in an animal where precise control of
ischemic time is possible, and the data we present should
be taken as a motivation and clinically relevant basis for de-
signing such studies.
It is important to note that the response to shear stress oc-
curs of a broad time frame. Mechanosensory signal on the
cell surface activates caveolin bound eNOS by phosphoryla-
tion on Ser1177,34,42 increasing NO concentrations before
any changes in gene transcription or protein production can
occur. The potent gaseous hormone effects smoothmuscle re-
laxation within seconds.42-45 At the same time, a different set
of adaptor molecules lead to myocyte enhancer factor 2 acti-
vation and KLF2 transcription,23,34,46 itself a transcription
factor inducing eNOS and TM, as well as inhibiting endothe-
lial inflammation.23 The need for 1 to 2 rounds of transcrip-
tion and translation extend the effects of shear stress to
hours, and modulation of coagulation and inflammation in-
fluence long-term microvascular modeling. We evaluated
only short-term events with our 3-hour SNMP model,33 and
will use our experience with perfusing livers up to 24 hours
to further study medium-term events. In addition, we have
developed a reperfusion simulation model on pump that will
be useful for evaluating livers at physiologic conditions after
SNMP. Small animal transplantation models will also prove
useful in observing long-term effects of the impaired NO re-
sponse in steatotic livers.
Finally, it is worth mentioning that steatotic livers may re-
spond differently to shear stress for reasons other than simple
topology. For example, NO production also responds to in-
flammatory stimuli via inducible nitric oxide synthase activity,
and Gehrau et al47,48 showed that proinflammatory cytokines
were significantly increased in steatotic grafts after reperfu-
sion. As a result, it is crucial to investigate the activity levels
of different NOS isoforms to assess the overall involvement
of different NO production processes. In our study, the NO
concentrations trended fairly closely with eNOS phosphoryla-
tion and presumably, activity levels. Additionally, there is rela-
tively little inducible nitric oxide synthase expression in the
liver49 (gtexportal.org and proteinatlas.org). Thus, we suspect
that the majority of the difference in NO levels was generated
by endothelial eNOS.
This study used SNMP as a method to assess the differ-
ences between steatotic and nonsteatotic livers during preser-
vation. Machine perfusion not only provides an opportunity
to assess the quality of grafts ex situ but also helps to improve
grafts.33 Strategies considered to improve endothelial func-
tion for steatotic livers to reduce tissue injury may includechemically increasing NO levels by adding NO donors into
the perfusion fluid. The use of statins may be promising
too. Statins were originally designed to decrease cholesterol
levels but they have also been found to be potent KLF2 acti-
vators with the potential to enhance eNOS levels and subse-
quently maintain NO bioavailability. Gracia-Sancho et al
have shown the beneficial effects of statins as prophylactic
treatment to prevent damage due to I/R injury in steatotic rat
livers.50 Administering statins to a potential donor is however
impractical and unethical. The same group has also shown
that the use of statins in cold storage solution improvedmicro-
circulation in rat livers and reduced I/R injury compared with
grafts preserved in cold storage solutionwithout statins.51 The
addition of statins to perfusion fluid in human livers has not
been examined yet but is worth investigating especially for
grafts with moderate/severe macrosteatosis to reduce primary
graft dysfunction rate that cannot be reduced bymeans of ma-
chine perfusion alone.
In conclusion, donor WIT, CIT, and macrosteatosis all ap-
pear to have an influence on NO production or availability,
and outcome variables may depend on a variety of interac-
tions of time and type of ischemia (warm or cold) and type
of liver (steatotic or nonsteatotic). While the heterogeneity
of deceased donor livers and relatively small groups makes
it difficult to interpret results, the pilot study data presented
here indicate that steatosis in human livers results in endothe-
lial dysfunction indicated by decreased upregulation of KLF2
and, less activation of eNOS and NO production. These re-
sults indicate research on this pathway, either with larger
sample sizes or better controlled animal models, as a profit-
able direction.
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